The amanitin derivative was conjugated to an anti-B-cell maturation antigen (BCMA) mAb (Scheme 19C) and was cytotoxic against both proliferating and resting myeloma cells in vitro, but not against BCMA-negative cells. Here, TNFRSF17 is linked to plasma cell myeloma.